Get Involved

group photo

Currently Recruiting Studies

  1. Title: Accelerated Bone Loss in Aging HIV-infected Individuals (Aging Bone)

    Purpose:
    Both HIV infection and the medications used to treat HIV (often referred to as HAART) cause bone loss. How this bone loss occurs is not completely understood. There is fear that as HIV infected people live longer because of HAART, that they will experience excessive bone loss and increased rate of bone fracture. We think that HIV infection affect the production of certain proteins that determine the density of the bone. Because of this, people aging with HIV infection may lose bone faster than people not infected by the virus. In this study, we will examine the amount of these bone proteins in the blood of both HIV+ and HIV- adults of different age groups. Finding out what cause bone loss in people living with HIV will enable us to find a solution that can prevent this loss.

    Eligibility:
    All genders, ages 18+, either HIV- with no major health problems or HIV+ and on medication for 2+ years with an undetectable viral load for a least 6 months

    Coordinator(s):
     Tina Tisdale and Brittney Fishback

    Contact Information: (404) 251-8927 and (404) 251-8928

  2. Title: IL-4 Bone Study

    Purpose:
    The purpose of this study is to look at bone loss in persons living with HIV. Both HIV infection and the medications used to treat HIV (often referred to as HAART) cause bone loss. How this bone loss occurs is not completely understood. There is fear that as HIV infected people live longer because of HAART, and that they will experience excessive bone loss and increased rate of bone fracture. We think that HIV infection affect the production of certain proteins including IL-4 that determine the density of the bone. Because of this, people with HIV infection may lose bone faster than people not infected by the virus. In this study, we will examine the amount of IL-4 and other bone proteins in the blood of both HIV+ and HIV- adults. Finding out what cause bone loss in people living with HIV will enable us to find a solution that can prevent this loss.

    Eligibility:
    All genders, ages 18+, either HIV- with no major health problems or HIV+ and medication naive (not currently and have never taken any HIV medications) but willing to start medications

    Coordinator(s):
    Tina Tisdale and Brittney Fishback

    Contact Information: (404) 251-8927 and (404) 251-8928
     
  3. Title: Anal Cancer HSIL Outcomes Research (ANCHOR)

    Purpose:
    The purpose of this study is to determine whether treating anal HSIL is effective in reducing the incidence of anal cancer in HIV-infected men and women.  While deaths from AIDS are way down, anal cancer among people living with HIV is on the rise. We think that anal cancer can be prevented by routine screening and removal of precancerous cells. This strategy has reduced cervical cancer rates by 80%. But to get the insurance companies to cover routine anal cancer screening and preventative treatment, we need to prove that this strategy actually prevents cancer. The best way to show that is to recruit people with High Grade Squamous Intraepithelial Lesions (HSIL) into a study and assign them randomly to a treatment arm or a monitoring arm. We then follow everyone for five years to compare the rates of cancer in both study arms. At the end of the study we’ll know whether screening and treatment of HSIL are effective strategies in preventing anal cancer. We’ll also learn a lot about HPV and other risk factors and why these sometimes cause cancer.

    Eligibility:
    All genders, ages 35+, HIV+

    Coordinator(s):
    Aubrey Cyphert

    Contact Information: (404) 251-8931

     
  4. Title: Women's Adherence and Visit Engagement (WAVE)

    Purpose:
     
    The purpose for the WAVE study is to address the gaps in knowledge relating to HIV-related stigma by leveraging the resources of the national Women’s Interagency HIV Study (WIHS), which has been collecting data on HIV-infected women’s treatment adherence, mental health, and immunologic and virologic outcomes for 20 years. In 2013, WIHS added new sites from the Southern US in response to shifts in the HIV epidemic, for which Emory University is one of the new sites from the Southern USA. The proposed study involves a yearly supplementary visit at three collaborating WIHS sites (n=500) representing different parts of the country – California (San Francisco), the Deep South (Alabama/Mississippi), and the Southeast (Georgia) – to collect additional measures of theoretically important dimensions of stigma, validated measures of hypothesized interpersonal, psychological, and mental health mechanisms, measures of other intersecting stigmas and discrimination (due to race, gender, and socio-economic status), as well as hair samples for assessment of cortisol (a biomarker for chronic stress).

    Eligibility:
    HIV+ women enrolled in WIHS

    Coordinator(s):
     
    Kayla Smith

    Contact Information: (404) 616-9724

  5. Title: Topical Curcumin for Precancer Cervical Lesions (Curcumin)

    Purpose:
     
    There is a desperate need for an inexpensive, non-invasive alternative method to treat premalignant cervical lesions.

    Curcumin, an extract from turmeric, a popular culinary spice, has been used in traditional Indian medicine for its anti- inflammatory and anti-infectious properties. Recent studies have shown the potential effect of curcumin to reduce tumors and precancerous lesions in animal and human cancer cells. It is postulated that curcumin achieves its effect on cancer cells by modulating different cellular pathways as well as altering HPV effect on tissue cells.

     We plan to explore the effect of curcumin as a potential medical treatment in HIV-infected women with HSIL lesions of the cervix. 40 women with HSIL of the cervix will be enrolled to either insert 2000 mg capsule of curcumin in their vagina daily or placebo. They will have regular monthly visits for 4 months and then undergo removal of the precancerous cells as recommended standard of care.  

    Eligibility: Women, ages 21+, HSIL cytology with no invasive features on colposcopy, not pregnant or breastfeeding

    Coordinator(s):
     
    Dr. Lisa Flowers

    Contact Information: (404) 778-1380 or email lflowe2@emory.edu

  6. Title: Grady Trauma Project (GTP)

    Purpose:
     
    Post-Traumatic Stress Disorder (PTSD) is a debilitating syndrome that occurs in only some people after exposure to traumatic events. Both genetic and psychological factors are thought to contribute to the vulnerability towards pathological response to trauma.This project aims to determine the relative contribution of genetic and trauma-related factors to risk for PTSD following trauma. We propose to study stress-related candidate genes that likely play important roles in mediating vulnerability to PTSD. This would be the first study to examine many of these genes that span a variety of functions including monoamine, neurotrophic, and hypothalamic-pituitary axis (HPA) regulation. In addition, we propose to study the interaction of these candidate genes with other known non-genetic risk factors. Finally, our proposal is novel because it will examine PTSD-related neuroendocrine and physiological endophenotypes that likely reflect the action of specific genes more directly than the complex diagnosis of PTSD itself.

    Eligibility: All genders, ages 18-65

    Coordinator(s): Rebecca Roffman

    Contact Information: (404) 251-8754

  7. Title: Doletegravir in Reservoirs (DTG)

    Purpose:
     The purpose of this study is to find out how well the HIV medication dolutegravir gets into different parts of the body: including blood plasma, special blood cells, and rectal tissue. Specifically, we want to compare how fast dolutegravir lowers the HIV viral load in these three different sites. In addition, we want to see if there are any differences in how dolutegravir acts in males and females. Results of this study will give us more information about HIV medications and their limitations. In the future, this could help us create better HIV medications that can get into these hard-to-reach places and eventually cure HIV infection.

    Eligibility:
    All genders, ages 18+, HIV+

    Coordinator(s):
     Nakita Brown

    Contact Information: (404) 616-9965

  8. Title: Pre-Exposure Prophylaxis to Prevent HIV Acquisition in US Women: A Demonstration Project (Women's PrEP Demo)

    Purpose:
     The overall aims of this study are to assess attitudes toward PrEP, feasibility of Truvada PrEP procurement through the established access procedures, and adherence to Truvada PrEP among US women at risk for HIV acquisition.

    Eligibility:
     Women, ages 18-65, HIV- at risk for HIV acquisition

    Coordinator(s):
     Nakita Brown

    Contact Information: (404) 616-9965